Seeking Alpha

RBC Capital's Jason Kantor weighs in on the news that Seattle Genetics (SGEN -0.3%) scored a...

RBC Capital's Jason Kantor weighs in on the news that Seattle Genetics (SGEN -0.3%) scored a victory with testing of its Adcetris drug for Hodgkin lymphoma, and is closing in on Phase III trials. The analysts say that if the drug becomes part of first-line treatment, it would "significantly increase" the target population for it by 4X-5X. "Most doctors we talk to believe Adcetris will ultimately become part of standard of care."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|